Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 4Phase 1 4

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 234Breast Neoplasms 234Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 135Colorectal Neoplasms 126Leukemia, Myeloid, Acute 123Lung Neoplasms 109Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 72Sarcoma 71Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 56Lymphoma, Non-Hodgkin 55Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 52Hematologic Neoplasms 52Endometrial Neoplasms 52Urinary Bladder Neoplasms 51Rectal Neoplasms 50

Interventions

niraparib 1liposomal doxorubicin 1inavolisib 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × 90 days × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05010031 2026-05-11

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT07522697 2026-04-13

MITO END-4

National Cancer Institute, Naples

Phase 2 Not yet recruiting
48 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡